




RealRate

PHARMACEUTICAL 2020

Minerva Neurosciences Inc.
Rank 270 of 358





RealRate

PHARMACEUTICAL 2020

Minerva Neurosciences Inc. Rank 270 of 358



The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is -38%, being 75% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	47,137
Cost of Goods Sold	0
Intangible Assets	30,069
Liabilities, Current	6,629
Liabilities, Non-Current	41,287
Other Assets	277
Other Compr. Net Income	0
Other Expenses	-2,254
Other Liabilities	1,803
Other Net Income	1,427
Other Revenues	0
Property and Equipment	16
Research and Development	58,124
Selling, General and Administrative Expense	17,741

Output Variable	Value in 1000 USD
Assets	77,499
Liabilities	49,719
Expenses	73,611
Revenues	0
Stockholders Equity	27,780
Net Income	-72,183
Comprehensive Net Income	-72,183
Economic Capital Ratio	-38%